Laennec AI, a pioneering medical AI company based in Cardiff, announces the successful completion of its pre-seed funding round. The company has secured investment from SFC Capital and OVC Ventures, along with grant funding from the Welsh Government, Innovate UK, and the National Institute for Health Research (NIHR). This combined support will accelerate the development of affordable medical devices, bringing healthcare closer to patients and ushering in a new era of self-care.
Harnessing cutting-edge technology to revolutionise healthcare, Laennec AI integrates advanced algorithms into a user-friendly mobile app, empowering patients to monitor chronic conditions like asthma, COPD, COVID-19, flu, heart failure, and arrhythmias from home while ensuring they are remotely monitored by clinicians. This innovation makes healthcare more accessible and represents a significant step towards the future of medical care.
Chronic diseases are leading causes of morbidity worldwide, especially in underserved areas with limited access to healthcare facilities. Traditional healthcare models struggle to meet the demands of growing populations and the increasing prevalence of chronic conditions. Laennec AI's solution addresses these challenges by making advanced diagnostic tools accessible and affordable, reducing healthcare inequalities, and improving patient outcomes.
The investment underscores the transformative potential of Laennec AI's technology and the growing recognition of innovative solutions advancing healthcare. The company plans to use the funding to scale operations, refine its AI-powered medical devices, and expand partnerships with healthcare providers and research institutions.
